Utility of cell population data (VCS parameters) as a rapid screening tool for Acute Myeloid Leukemia (AML) in resource ‐constrained laboratories

Journal of Clinical Laboratory Analysis, EarlyView.
Source: Journal of Clinical Laboratory Analysis - Category: Laboratory Medicine Authors: Source Type: research

Related Links:

Authors: Matza LS, Deger KA, Howell TA, Koetter K, Yeager AM, Hogge D, Fisher V, Louie AC, Chung KC Abstract Aims Acute myeloid leukemia (AML) treatment typically involves remission induction chemotherapy followed by consolidation chemotherapy. New treatments for AML have recently been introduced, including a chemotherapy formulation called CPX-351, which is administered via less time-intensive IV infusion than the standard "7 + 3" continuous infusion regimen of cytarabine plus an anthracycline. The purpose of this study was to estimate utilities that could be used in economic modeling of AM...
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
Authors: Cioccio J, Claxton D Abstract INTRODUCTION: Tyrosine kinases (TKs) drive cell survival and proliferation in many normal and malignant cell types. TKs are frequently mutated in acute myeloid leukemia (AML) and hence are increasingly targeted. The management of AML has dramatically improved because of TKI-targeted treatment. Areas Covered: This review provides a biological background for TK inhibitors (TKIs) in AML and reviews their use in the clinic. TK expression and mutation in AML are explored with a focus on TKs associated with specific AML subsets and treatment outcomes. TKIs that specifically target F...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
We reported that CuB suppressed growth and induced apoptosis in AML cells. The inhibition of growth and activation of apoptosis were mediated through CuB-induced downregulation of the CIP2A/PP2A/C-KIT signal pathway. Furthermore, CuB inactivated the JAK2 and STAT3 molecules downstream of C-KIT via the downregulation of CIP2A. These results advance our understanding of CuB-induced growth inhibition and apoptosis and support further investigation of CuB as a CIP2A inhibitor for AML therapies.
Source: Journal of Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research
Conditions:   Acute Myeloid Leukemia;   AML Interventions:   Drug: Palcociclib;   Drug: CPX-351 Sponsor:   Aziz Nazha Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Acute Myeloid Leukemia Interventions:   Drug: Decitabine;   Drug: Venetoclax Sponsors:   University of Chicago;   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Louise Moreton, from Melbourne, started feeling run-down after moving to Durham, England, with her husband and their son. She was quickly diagnosed with acute myeloid leukaemia.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
AbstractIvosidenib (Tibsovo®), a first-in-class, small molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), is an important new therapeutic option in the USA for treating adults with relapsed or refractory acute myeloid leukemia who have a susceptibleIDH1 gene mutation. In such patients, oral ivosidenib is effective and generally well tolerated, producing encouraging rates and durations of complete remission (CR), CR or CR with partial hematologic recovery (CR/CRh), overall response, and overall survival. CR/CRh rates are consistent across most baseline characteristics. Ivosidenib also provides additional cl...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
Condition:   Acute Myeloid Leukemia Interventions:   Drug: Decitabine;   Drug: Venetoclax Sponsors:   University of Chicago;   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 16 February 2019Source: Best Practice &Research Clinical HaematologyAuthor(s): Taha Al-Juhaishi, Arushi Khurana, Danielle ShaferAbstract:Treatment for Hodgkin (HL) and non-Hodgkin’s lymphoma (NHL) has changed dramatically in the last fifty years. While there are increasing numbers of long-term survivors, there has been increasing recognition of the long-term toxicities of treatments, particularly therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML). The survival for t-MDS/AML is extremely poor. Multiple heterogeneous retrospective studies have reported...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: April 2019Source: Cancer Epidemiology, Volume 59Author(s): Paraskevi Panagopoulou, Alkistis Skalkidou, Erin Marcotte, Friederike Erdmann, Xiaomei Ma, Julia E. Heck, Anssi Auvinen, Beth A. Mueller, Logan G. Spector, Eve Roman, Catherine Metayer, Corrado Magnani, Maria S. Pombo-de-Oliveira, Michael E. Scheurer, Ana-Maria Mora, John D. Dockerty, Johnni Hansen, Alice Y. Kang, Rong Wang, David R. DoodyAbstractBackgroundParental age has been associated with several childhood cancers, albeit the evidence is still inconsistent.AimTo examine the associations of parental age at birth with acute myeloid leukemia (AM...
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Laboratory Medicine | Leukemia